#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Dementia Alzheimer's type Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Arteriosclerosis Infertility male Thrombocytosis Corneal neovascularisation Antiphospholipid syndrome Duchenne muscular dystrophy Albright's disease Immunodeficiency Fragile X syndrome Lip and/or oral cavity cancer Pneumonia Fms-like tyrosine kinase 3 positive Sarcoma Ocular myasthenia Hepatic cirrhosis More trials…

    Learn about Rare Diseases

    KBG syndrome – Trials in Disease Progressive supranuclear palsy – Treatment Mantle cell lymphoma – Diagnostics Rett syndrome – Trials in Disease Uterine leiomyosarcoma – Basic Information Atypical haemolytic uraemic syndrome – Treatment Hereditary ataxia Immunodeficiency congenital – Basic Information Langerhans’ cell histiocytosis – Treatment Osteosarcoma – Life with Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Fentanyl Citrate Zilucoplan Sodium Levosimendan Follitropin Alfa Avalglucosidase Alfa Niflumic Acid ROC-101 HYDROCHLORIDE Ads-013 Cagrilintide Diltiazem ZINC CHLORIDE Dupilumab RNMB1 Atropine Sulfate Isoprenaline Hydrochloride Finasteride Bupropion Hydrochloride IADADEMSTAT Gindameran Specific Nucleic Acid Sna-Papi More therapies…

    Learn about Your Condition

    Colour blindness Diabetic retinal oedema Cluster headache Malignant mast cell neoplasm Cervix carcinoma stage IV Autoimmune uveitis Malignant melanoma stage IV Breast cancer stage II Lichenoid keratosis Asymptomatic HIV infection Cartilage injury Tendon disorder Appendicitis perforated Myocarditis post infection Tricuspid valve disease More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Relapsing multiple sclerosis

  • A study to evaluate the safety and how the body uses ublituximab injections in patients with multiple sclerosis

    Recruiting

    2 1 1 1
    Investigated Drugs:
    • Ublituximab
    Poland

  • Study of ublituximab compared to fingolimod for children and teenagers aged 10 to 17 years with relapsing multiple sclerosis

    Recruiting

    4 1 1
    Investigated Drugs:
    • Ublituximab
    • Fingolimod
    Poland Slovakia

  • Study comparing remibrutinib and ocrelizumab in patients with relapsing multiple sclerosis who switch from ocrelizumab treatment

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Relapsing multiple sclerosis
    Investigated Drugs:
    • Remibrutinib
    • Ocrelizumab
    Belgium Czechia Denmark France Germany Greece +4

  • Study on the Safety and Effects of YTB323, Tocilizumab, and Cyclophosphamide in Patients with Relapsing Multiple Sclerosis Who Have Active Disease Despite Treatment

    Recruiting

    1 1 1 1
    Investigated Drugs:
    • Fludarabine Phosphate
    • Rapcabtagene Autoleucel
    • Cyclophosphamide
    France Germany Italy Spain

  • Study on the Effectiveness of Ublituximab and Drug Combination for Patients with Relapsing Multiple Sclerosis

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Relapsing multiple sclerosis
    Investigated Drugs:
    • Cetirizine
    • Gadobutrol
    • Ublituximab
    Poland

  • Study on Long-Term Safety of Tolebrutinib and Teriflunomide for Patients with Multiple Sclerosis

    Recruiting

    3 1 1
    Investigated Diseases:
    • Progressive relapsing multiple sclerosis
    • Secondary progressive multiple sclerosis
    • Relapsing multiple sclerosis
    Investigated Drugs:
    • Anhydrous Cholestyramine
    • Magnetic Resonance Imaging Contrast Media
    • Teriflunomide
    Austria Belgium Bulgaria Croatia Czechia Denmark +17
1 2 3 4
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!